VENTURE CAPITAL POST

GSK resolves California lawsuit over Zantac cancer claims in a confidential settlement, avoiding trial amid ongoing legal battles.

A gene therapy for Bubble Boy Disease has received positive evaluation from European regulatory panel, paving a way for official approval. Currently, there’s no gene therapy for the disease, and the therapy would enhance patient’s success in survival and even recovery.

GlaxoSmithKline (GSK.L) may ditch a plan to return 4 billion pounds ($6.1 billion) to investors, some analysts believe, as the drugmaker prepares to set out its vision for the reshaped group and a new chairman takes the helm.

GlaxoSmithKline (GSK.L) has taken profits in Aspen Pharmacare (APNJ.J) by selling half its stake in the South African drugmaker for $853 million, following a long investment in the firm.

First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.

GlaxoSmithKline is feeling the heat from the rapid growth in electronic cigarettes, with enthusiasm for the nicotine delivery devices dampening sales of the British drugmaker's patches and gum, its chief executive said.

Belgian biotech group Galapagos said on Tuesday that its research partner Janssen Pharmaceutica, a unit of Johnson & Johnson, had pulled out of a program to develop a new drug to treat bowel disease.

GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers.

GlaxoSmithKline (GSK.L) said on Wednesday it would shed "several hundred" U.S. commercial jobs and a similar number of research positions as it restructures operations in its biggest market, where drug sales are flagging.

Drugmakers are looking for some kind of indemnity from governments or multilateral agencies against possible losses or claims arising from the widespread emergency use of new Ebola vaccines in Africa.

Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

Vernalis is pleased to announce the achievement of the first milestone in its research collaboration with Asahi Kasei Pharma (AKP).

GSK had agreed to put its thromobosis drugs on sale to Aspen Pharmacare with proceeds to be used for general corporate purposes.

Xinhua reported that French drugmaker Sanofi had become the focus of bribery investigations by Chinese authorities.

GlaxoSmithKline (GSK), the biggest pharmaceutical firm in Britain, launched a USD 50 million venture capital fund for bioelectronic medicines and technologies.